Company intelligence / Profile preview

First Step

Seongnam-si, Gyeonggi-do, South Korea

Ownership: Private
Employees: ~50
Development stage: Other

Overview

1ST Biotherapeutics is a clinical-stage biotechnology company dedicated to developing breakthrough therapies for neurodegenerative diseases and immuno-oncology. The company leverages its proprietary 1ST-FINDER platform, which focuses on induced proximity and targeted protein degradation, to discover novel small molecule candidates. Its lead program, FB-101, is a brain-penetrant c-Abl inhibitor currently in Phase 1 clinical trials for the treatment of Parkinson's disease and ALS. Additionally, the company is advancing a robust pipeline of kinase inhibitors and degraders targeting HPK1 and LRRK2 to address significant unmet medical needs in cancer and CNS disorders.

Therapeutic areas: OncologyNeurology
Modalities: Small moleculeTargeted protein degradation
Industry: Biotech

Partnerships

LigaChem Bio

Beyond the preview

Go deeper on First Step.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on First Step.

Explore the full profile